Literature DB >> 29649790

Evolution of multiple sclerosis prevalence and phenotype in Latin America.

L Negrotto1, J Correale2.   

Abstract

BACKGROUND: Literature regarding MS epidemiology and phenotype is scarce but has increased markedly over the past years. The objective of the present work is to assess the evolution of the prevalence and phenotype of MS in Latin America during recent years.
METHODS: Review of literature.
RESULTS: MS prevalence levels are low to medium in Latin America, although these have increased in recent years. A small latitudinal gradient has also been observed, but exceptions to this rule exist, suggesting other genetic and environmental factors ultimately influence regional prevalence rates. One of the distinctive features of the region is the complex genetic admixture arising from multiple divergent population ancestries in different countries including: Native Americans, Caucasians and Africans. Another variable which would lower MS risk in the region could be a protective effect linked to exposure to certain infections, such as parasites. Despite differences in MS epidemiology, Latin American patients show an MS phenotype very similar to that of Caucasian patients, and a progressively increasing female gender ratio as has been described worldwide.
CONCLUSION: MS epidemiology in Latin American patients has distinctive features. Both, prevalence and incidence, are increasing.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Incidence; Latin America; Multiple sclerosis; Phenotype; Prevalence

Mesh:

Year:  2018        PMID: 29649790     DOI: 10.1016/j.msard.2018.03.014

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  5 in total

1.  Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Cohort Study.

Authors:  Martha Rocio Hernández-Preciado; Jazmin Marquez-Pedroza; Nayeli Alejandra Sánchez-Rosales; José de Jesús García-Rivera; Antonio Kobayashi-Gutiérrez; Blanca Miriam Torres-Mendoza; Efraín Chavarría-Avila; Raúl Alejandro Montaño-Serrano; Fernando Cortes-Enriquez; Mario Alberto Mireles-Ramírez
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

Review 2.  Impact of sex hormones on immune function and multiple sclerosis development.

Authors:  María C Ysrraelit; Jorge Correale
Journal:  Immunology       Date:  2018-10-11       Impact factor: 7.397

3.  Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis.

Authors:  Yumeng Song; Yongfeng Lao; Fuxiang Liang; Jing Li; Bibo Jia; Zixuan Wang; Xu Hui; Zhenxing Lu; Biao Zhou; Wei Luo; Bing Song
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

4.  Prevalence of multiple sclerosis in Cuenca, Ecuador.

Authors:  Edgar Patricio Correa-Díaz; María Angélica Ortiz; Ana María Toral; Fernando Guillen; Enrique Terán; Daniel Ontaneda; María García-Castillo; Carolina Jácome-Sánchez; Germaine Torres-Herrán; Andrés Ortega-Heredia; María Eugenia Buestán; Juan Murillo-Calle; Praneeta Raza; Guillermo Baño
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-10-30

5.  Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis.

Authors:  Sergio Sauri-Suárez; Sandra Quiñones-Aguilar; Arturo Contreras-Marín; Erik Omar Ramiro-Guerrero; David Zúñiga-García; Leticia Salinas-Vázquez; Leonardo Llamas-López; Carolina León-Jiménez; Adriana García-Martell; Iliana González-Hernández; Erwin Chiquete; Silvia García
Journal:  PLoS One       Date:  2020-04-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.